Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

abbott laboratories - ABT

ABT

Close Chg Chg %
104.06 0.50 0.48%

Open Market

104.56

+0.50 (0.48%)

Volume: 893.03K

Last Updated:

Mar 25, 2026, 10:45 AM EDT

Trade Now

Company Overview: abbott laboratories - ABT

ABT Key Data

Open

$105.45

 Day Range

104.25 - 105.82

52 Week Range

102.41 - 139.05

 Market Cap

$180.82B

Shares Outstanding

1.74B

 Public Float

1.73B

Beta

0.74

 Rev. Per Employee

N/A

P/E Ratio

27.98

 EPS

$3.73

Yield

230.64%

 Dividend

$0.63

EX-DIVIDEND DATE

Apr 15, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

12.63M

  

ABT Performance

1 Week
 
 -0.58%
 
1 Month
 
 -9.88%
 
3 Months
 
 -16.01%
 
1 Year
 
 -19.85%
 
5 Years
 
 -14.11%
 

ABT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 32
Full Ratings ➔

About abbott laboratories - ABT

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

ABT At a Glance

Abbott Laboratories
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
Phone 1-224-667-6100 Revenue 44.33B
Industry Medical Specialties Net Income 6.50B
Sector Health Technology 2025 Sales Growth 5.669%
Fiscal Year-end 12 / 2026 Employees 115,000
View SEC Filings

ABT Valuation

P/E Current 28.197
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 33.694
Price to Sales Ratio 4.941
Price to Book Ratio 4.174
Price to Cash Flow Ratio 22.89
Enterprise Value to EBITDA 19.758
Enterprise Value to Sales 5.072
Total Debt to Enterprise Value 0.063

ABT Efficiency

Revenue/Employee 385,460.87
Income Per Employee 56,521.739
Receivables Turnover 5.591
Total Asset Turnover 0.527

ABT Liquidity

Current Ratio 1.576
Quick Ratio 1.183
Cash Ratio 0.542

ABT Profitability

Gross Margin 52.727
Operating Margin 18.643
Pretax Margin 19.099
Net Margin 14.663
Return on Assets 7.732
Return on Equity 13.027
Return on Total Capital 9.809
Return on Invested Capital 10.472

ABT Capital Structure

Total Debt to Total Equity 27.117
Total Debt to Total Capital 21.332
Total Debt to Total Assets 16.302
Long-Term Debt to Equity 20.769
Long-Term Debt to Total Capital 16.339
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Abbott Laboratories - ABT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
43.65B 40.11B 41.95B 44.33B
Sales Growth
+1.34% -8.12% +4.59% +5.67%
Cost of Goods Sold (COGS) incl D&A
21.33B 20.07B 20.63B 20.95B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.27B 3.24B 3.22B 3.12B
Depreciation
1.25B 1.28B 1.34B 1.43B
Amortization of Intangibles
2.01B 1.97B 1.88B 1.68B
COGS Growth
+7.40% -5.90% +2.76% +1.60%
Gross Income
22.32B 20.04B 21.32B 23.37B
Gross Income Growth
-3.84% -10.24% +6.43% +9.60%
Gross Profit Margin
+51.14% +49.96% +50.83% +52.73%
2022 2023 2024 2025 5-year trend
SG&A Expense
13.96B 13.60B 14.47B 15.11B
Research & Development
2.85B 2.72B 2.82B 2.89B
Other SG&A
11.11B 10.88B 11.65B 12.22B
SGA Growth
-0.38% -2.57% +6.41% +4.39%
Other Operating Expense
- - - -
-
Unusual Expense
209.00M 188.00M (2.00M) 170.00M
EBIT after Unusual Expense
8.15B 6.25B 6.85B 8.09B
Non Operating Income/Expense
468.00M 1.11B 763.00M 897.00M
Non-Operating Interest Income
183.00M 385.00M 344.00M 308.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
315.00M 698.00M 603.00M 525.00M
Interest Expense Growth
-23.17% +121.59% -13.61% -12.94%
Gross Interest Expense
315.00M 698.00M 603.00M 525.00M
Interest Capitalized
- - - -
-
Pretax Income
8.31B 6.66B 7.01B 8.47B
Pretax Income Growth
+1.16% -19.77% +5.24% +20.72%
Pretax Margin
+19.03% +16.61% +16.72% +19.10%
Income Tax
1.37B 941.00M (6.39B) 1.94B
Income Tax - Current - Domestic
1.31B 528.00M 497.00M 387.00M
Income Tax - Current - Foreign
723.00M 874.00M 1.07B 1.11B
Income Tax - Deferred - Domestic
(610.00M) (382.00M) (459.00M) (257.00M)
Income Tax - Deferred - Foreign
(49.00M) (79.00M) (7.50B) 698.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
(28.00M) (22.00M) (51.00M) (24.00M)
Consolidated Net Income
6.91B 5.70B 13.35B 6.50B
Minority Interest Expense
- - - -
-
Net Income
6.91B 5.70B 13.35B 6.50B
Net Income Growth
-1.95% -17.44% +134.19% -51.31%
Net Margin Growth
+15.82% +14.21% +31.83% +14.66%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
6.91B 5.70B 13.35B 6.50B
Preferred Dividends
- - - -
-
Net Income Available to Common
6.91B 5.70B 13.35B 6.50B
EPS (Basic)
3.939 3.2764 7.673 3.7335
EPS (Basic) Growth
-0.71% -16.82% +134.19% -51.34%
Basic Shares Outstanding
1.75B 1.74B 1.74B 1.74B
EPS (Diluted)
3.9144 3.2596 7.6379 3.7185
EPS (Diluted) Growth
-0.56% -16.73% +134.32% -51.32%
Diluted Shares Outstanding
1.76B 1.75B 1.75B 1.75B
EBITDA
11.63B 9.68B 10.07B 11.38B
EBITDA Growth
-8.71% -16.78% +4.04% +13.02%
EBITDA Margin
+26.64% +24.13% +24.00% +25.67%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 133.84
Number of Ratings 32 Current Quarters Estimate 1.151
FY Report Date 03 / 2026 Current Year's Estimate 5.66
Last Quarter’s Earnings 1.50 Median PE on CY Estimate N/A
Year Ago Earnings 5.15 Next Fiscal Year Estimate 6.239
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 25 25 27 25
Mean Estimate 1.15 1.38 5.66 6.24
High Estimates 1.18 1.44 5.77 6.38
Low Estimate 1.12 1.31 5.45 5.99
Coefficient of Variance 1.13 2.05 1.34 1.19

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 19 18 17
OVERWEIGHT 5 4 4
HOLD 8 10 11
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Abbott Laboratories - ABT

Date Name Shares Transaction Value
Mar 6, 2026 Daniel Gesua Sive Salvadori EVP AND GROUP PRESIDENT 147,262 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.26 per share 17,120,680.12
Mar 6, 2026 Eric Shroff Senior Vice President 39,164 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $115.58 per share 4,526,575.12
Mar 6, 2026 Eric Shroff Senior Vice President 39,873 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.26 per share 4,635,634.98
Mar 6, 2026 Louis H Morrone EXECUTIVE VICE PRESIDENT 76,843 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $115.58 per share 8,881,513.94
Mar 6, 2026 Louis H Morrone EXECUTIVE VICE PRESIDENT 77,987 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.26 per share 9,066,768.62
Mar 6, 2026 Christopher Scoggins EXECUTIVE VICE PRESIDENT 77,126 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.26 per share 8,966,668.76
Mar 6, 2026 John A. McCoy VICE PRESIDENT AND CONTROLLER 24,628 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $115.58 per share 2,846,504.24
Mar 6, 2026 John A. McCoy VICE PRESIDENT AND CONTROLLER 25,213 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.26 per share 2,931,263.38
Mar 6, 2026 Robert B. Ford CHAIRMAN AND CEO; Director 306,461 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.26 per share 35,629,155.86
Mar 6, 2026 Mary K. Moreland EXECUTIVE VICE PRESIDENT 104,291 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $115.58 per share 12,053,953.78
Mar 6, 2026 Mary K. Moreland EXECUTIVE VICE PRESIDENT 104,904 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.26 per share 12,196,139.04
Mar 6, 2026 Lisa D. Earnhardt EVP AND GROUP PRESIDENT 90,407 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.26 per share 10,510,717.82
Mar 6, 2026 Daniel Gesua Sive Salvadori EVP AND GROUP PRESIDENT 146,377 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $115.58 per share 16,918,253.66
Mar 5, 2026 Philip P. Boudreau EVP AND CFO 71,172 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.26 per share 8,274,456.72
Mar 5, 2026 Elizabeth Cushman EVP, GC AND SECRETARY 38,836 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $116.26 per share 4,515,073.36
Mar 5, 2026 Elizabeth Cushman EVP, GC AND SECRETARY 38,573 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $115.58 per share 4,458,267.34
Jan 7, 2026 Michael F. Roman Director 5,882 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 Robert J. Alpern Director 10,409 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 Paola Gonzalez Director 5,208 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 7, 2026 John G. Stratton Director 13,034 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Abbott Laboratories in the News

Baby formula maker fills supply gap

While the U.S. is likely months away from seeing more baby formula back on the shelves, one company is looking to help fill the gap.